Per Bo Pedersen Fischer
Chief Executive Officer presso Helion Biotech ApS
Profilo
Per Bo Pedersen Fischer is the founder and the Chief Executive Officer of Helion Biotech ApS, which was founded in 2008.
He is also currently the Chief Executive Officer of Minervax ApS.
Dr. Fischer previously held the position of President & Chief Executive Officer at Azanta Danmark A from 2000 to 2003.
He also worked as a Principal at Novo Nordisk A and Bavarian Nordic A.
Dr. Fischer obtained a doctorate degree from the University of Oxford in 1996 and a graduate degree from the University of Southern Denmark in 1992.
Posizioni attive di Per Bo Pedersen Fischer
| Società | Posizione | Inizio |
|---|---|---|
Helion Biotech ApS
 Helion Biotech ApS Pharmaceuticals: MajorHealth Technology Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark. | Chief Executive Officer | 01/01/2008 |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Chief Executive Officer | 05/04/2011 |
Precedenti posizioni note di Per Bo Pedersen Fischer
| Società | Posizione | Fine |
|---|---|---|
Azanta Danmark A/S
 Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | President | 01/01/2003 |
| BAVARIAN NORDIC A/S | Corporate Officer/Principal | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Formazione di Per Bo Pedersen Fischer
| University of Oxford | Doctorate Degree |
| University of Southern Denmark | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| BAVARIAN NORDIC A/S | Health Technology |
| Aziende private | 3 |
|---|---|
Azanta Danmark A/S
Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | Health Technology |
Helion Biotech ApS
Helion Biotech ApS Pharmaceuticals: MajorHealth Technology Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark. | Health Technology |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Borsa valori
- Insiders
- Per Bo Pedersen Fischer
